Fludarabine-induced eosinophilia: case report.
Eosinophilia induced by nucleoside analogs has been described in a handful of case reports and during the treatment of both chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL). This paper reports an additional case of fludarabine-induced eosinophilia during the treatment of CLL. The patient, a 58-year-old man, developed peripheral eosinophilia with a peak value of 1.7x10(9)/l 5 months after the beginning of treatment with fludarabine. A thorough investigation for other causes of eosinophilia was negative and the eosinophilia subsided after the completion of the treatment.
Voutsadakis
I A
IA
Sérvice d'Hématologie, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France. voutsadakis@igr.fr
D000970:Antineoplastic Agents / Q000009:adverse effects*; D004802:Eosinophilia / Q000139:chemically induced*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine